Potential influence of lipids in diabetic nephropathy: Insights from experimental data and clinical studies

Diabetes and Metabolism

Volumn 26, Issue 4, 2000, Pages 254-264

  Bonnet, F ^a   Cooper, M E ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

Albuminuria; Angiotensin II; Diabetic nephropathy; Lipids; Lipoproteins

Indexed keywords

ANGIOTENSIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CORRELATION FUNCTION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROTEINURIA; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMAL; APOLIPOPROTEINS E; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DIABETIC NEPHROPATHIES; HUMAN; LIPIDS; LIPOPROTEINS; POLYMORPHISM (GENETICS); SUPPORT, NON-U.S. GOV'T;

EID: 0033808034     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. The role of lipid deposition in renal arteriolar sclerosis
2. Dietary induced glomerulosclerosis in the guinea pig
3. Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long term studies
4. Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats
5. The renal injury of diet-induced hypercholesterolemia in rats
6. Effects of genetic obesity on renal structure and function in the Zucker rat
7. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease
8. Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis
9. Cholesterol: A renal risk factor in diabetic nephropathy
10. Hypercholesterolemia: A determinant of renal function loss and death in IDDM patients with nephropathy
11. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE-inhibitors
12. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion
13. Plasma lipid and coagulation factor concentrations in insulin-dependent diabetics with microalbuminuria
14. Lipoprotein abnormalities in diabetic nephropathy
15. The compositional abnormalities of lipoproteins in diabetic renal failure
16. Plasma cholesteryl ester transfer protein and its relationship to plasma lipoproreins and apolipoprotein A-I containing lipoproteins in IDDM patients with microalbuminuria and clinical nephropathy
17. Multiple lipoprotein abnormalities in type I diabetic patients with renal disease
18. Relationship of progressively increasing albuminuria to apoprotein[a] and blood pressure in type 2 (non insulin-dependent) and type 1 (insulin-dependent) diabetic patients
19. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy
20. New insights into lipid metabolism in the nephrotic syndrome
21. Pattern of hyperlipoproteinemia in human nephrotic syndrome: Influence of renal failure and diabetes mellitus
22. Dyslipoproteinemia in diabetic renal failure
23. Hyperlipidemia and progressive renal disease
24. Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic end-stage renal disease
25. Abnormalities in lipoprotein metabolism in hemodialysis patients
26. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
27. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in the rat 5/6 nephrectomy model of chronic renal failure
28. Characterization of the binding of low density lipoproteins to cultured rat mesangial cells
29. Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells
30. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney-diseases
31. Early glomerular changes in rats with dietary-induced hypercholesterolemia
32. Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis
33. Cellular mechanisms of lipid injury in the glomerulus
34. The role of oxidatively modified lipoproteins in lipid nephropathy
35. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?
36. Pathogenesis, prevention, and treatment of diabetic nephropathy
37. Low-density lipoprotein stimulation of mesangial cell fibronectin synthesis: Role of protein kinase C and transforming growth factor-β
38. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells
39. Cholesterol, macrophages, and gene expression of TGF-β1 and fibronectin during nephrosis
40. Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats
41. The effects of dietary cholesterol on experimental diabetic nephropathy
42. Modulation of glomerulosclerosis and interstitial fibrosis by native and modified lipoprotein
43. Understanding the nature of renal disease progression
44. Impact of hyperglycemia on the renin angiotensin system in early human type I diabetes mellitus
45. Fosinopril ameliorates exogenous cholesterol-induced incipient glomerular lesions in obese Zucker rats. Effects on eicosanoid secretion
46. Selected aspects of ACE inhibitor therapy for patients with renal disease: Impact on proteinuria, lipids and potassium
47. Apolipoprotein B independently predicts progression of very-low-level albuminuria in insulin-dependent diabetes
48. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study
49. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM
50. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia
51. Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten year's experience
52. Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study
53. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients
54. Proteinuria in NIDDM in South India: Analysis of predictive factors
55. Urinary albumin excretion rate and its determinant after 6 years in non-insulin-dependent diabetic patients
56. Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patientsa 10 year follow-up study
57. Apolipoprotein E alleles, dyslipidemia and coronary artery disease: The Framingham Offspring Study
58. Association of apolipoprorein ε2 allele with diabetic nephropathy in Caucasian subjects with NIDDM
59. Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients
60. Apolipoprotein E genotypes and risk of diabetic nephropathy
61. Lack of contribution of lipid gene polymorphisms to IDDM nephropathy - The GENEDIAB Study
62. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy
63. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM
64. Apo E polymorphism and albuminuria in diabetes mellitus: A role for LDL in the development of nephropathy in NIDDM?
65. Lovastadn preserves renal function in experimental diabetes
66. Lovastatin inhibits transforming growth factor-betal expression in diabetic rat glomeruli and cultured rat mesangial cells
67. Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy
68. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats
69. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats
70. Lovastatin inhibits proliferation of rat mesangial cells
71. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Survival Study (4S)
72. Partial remission of nephrotic syndrome in patient on long-term simvastatin
73. Effect of lipid-lowering therapy on the progression of renal disease in nondiabetic patients
74. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone
75. Lipid-lowering therapy in membranous nephropathy
76. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus
77. Decreased albuminuria by pravastatin in hyperlipidemic diabetics
78. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
79. Reduction of albumin excretion rate in mormotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
80. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
81. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients
82. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria
83. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?
84. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
85. Why is proteinuria such an important risk factor for progression in clinical trials?